35 U.S. lawmakers have disclosed 119 Bristol-Myers Squibb Company trades under the STOCK Act — 66 buys and 53 sells between 2013 and 2026. Congress has been net buyers of BMY, and their disclosed buys are up 12.5% versus the latest close.
*Notional-weighted price return on lawmakers' disclosed buys of BMY, marked to the latest close — per-share (share counts aren't disclosed).
Lawmakers ranked by notional-weighted return on their disclosed BMY buys (last ~3y), marked to the latest close.
| Date | Member | Type | Amount | Est. price | Latest close | Return |
|---|---|---|---|---|---|---|
| 2015-09-15 | Robert J. Wittman | BUY | $1K–$15K | $60.09 | $63.83 2026-08-14 | +6.2% |
| 2015-07-14 | George Holding | BUY | $1K–$15K | $70.06 | $63.83 2026-08-14 | -8.9% |
| 2015-04-28 | James B. Renacci | BUY | $1K–$15K | $64.54 | $63.83 2026-08-14 | -1.1% |
| 2015-03-27 | JAMES M INHOFE | BUY | $1K–$15K | $65.26 | $63.83 2026-08-14 | -2.2% |
| 2015-03-17 | James B. Renacci | BUY | $1K–$15K | $67.62 | $63.83 2026-08-14 | -5.6% |
| 2015-02-23 | Sheldon Whitehouse | BUY | $1K–$15K | $61.29 | $63.83 2026-08-14 | +4.1% |
| 2015-01-22 | Kenny Marchant | BUY | $1K–$15K | $62.09 | $63.83 2026-08-14 | +2.8% |
| 2015-01-05 | James B. Renacci | BUY | $1K–$15K | $58.58 | $63.83 2026-08-14 | +9.0% |
| 2014-10-14 | Sheldon Whitehouse | BUY | $1K–$15K | $48.92 | $63.83 2026-08-14 | +30.5% |
| 2014-10-14 | Sheldon Whitehouse | BUY | $1K–$15K | $48.92 | $63.83 2026-08-14 | +30.5% |
| 2014-09-18 | Sheldon Whitehouse | BUY | $1K–$15K | $51.12 | $63.83 2026-08-14 | +24.9% |
| 2014-07-15 | Sheldon Whitehouse | BUY | $1K–$15K | $48.71 | $63.83 2026-08-14 | +31.0% |
| 2014-06-19 | Susan M Collins | SELL | $1K–$15K | $47.84 | $63.83 2026-08-14 | -33.4% exit |
| 2014-06-19 | Susan M Collins | SELL | $1K–$15K | $47.84 | $63.83 2026-08-14 | -33.4% exit |
| 2014-06-19 | Susan M Collins | SELL | $1K–$15K | $47.84 | $63.83 2026-08-14 | -33.4% exit |
| 2013-01-14 | SUSAN M COLLINS | SELL | $1K–$15K | $34.22 | $63.83 2026-08-14 | -86.5% exit |
| James B. Renacci | BUY | $1K–$15K | — | — | — | |
| James B. Renacci | BUY | $1K–$15K | — | — | — | |
| John A. Yarmuth | BUY | $1K–$15K | — | — | — |
Return: buys marked to the latest close (open); sells tagged rt are realized round-trips vs a prior disclosed buy; exit = timing (stock move after the sale, seller's perspective).
35 members of the U.S. House and Senate have disclosed Bristol-Myers Squibb Company transactions under the STOCK Act — 66 purchases and 53 sales. The full member-by-member breakdown, with dates and dollar ranges, is in the table above.
No member of Congress has disclosed a BMY purchase in the last 90 days. STOCK Act filings lag the trade by up to 45 days, so newer buys may still be pending disclosure.
Notional-weighted, lawmakers' disclosed BMY buys are up 12.5% versus the latest close of $63.83. Each trade's own return — and realized round-trips on matched sells — is in the Return column.
Yes. Under the 2012 STOCK Act, members of Congress may buy and sell individual stocks but must publicly disclose each transaction within 45 days. Bargo surfaces those filings so you can see who traded BMY and how it performed.